Table 5

Suggested approach to screening, diagnosis and management of pulmonary hypertension in SCD

1. Screening for pulmonary hypertension by echocardiography 
 • Perform echocardiography every 1 to 3 y, OR 
 • Perform echocardiography based on one or more findings consistent with increased risk: 
  – Dyspnea on exertion 
  – Limited exercise capability as determined by the 6-minute walk test (<350 m) 
  – History of thromboembolism 
  – Pulse oximetry <96% at rest 
  – Previous echocardiogram with TRV of ≥2.5 m/sec 
  – Physical findings of right-sided heart failure: lower extremity edema, hepatomegaly, or jugular venous distension 
  – Elevated serum N-terminal proBNP concentration 
  – Elevated serum creatinine concentration (>1.0 mg/dL for severe sickling phenotype and >1.4 mg/dL for mild sickling phenotype) 
  – LDH >475 U/L or reticulocyte count >300 000 
  – Serum ferritin >1000 ng/ml 
2. Actions to be taken based on the results of echocardiography 
 • TRV <2.5 m/sec: Ensure that patient is being managed according to NHLBI guidelines83  
 • TRV 2.5-2.9 m/sec, right ventricle normal by echocardiography, no findings suggestive of pulmonary hypertension: Ensure patient being managed according to NHLBI guidelines83  and repeat echocardiogram yearly 
 • TRV 2.5-2.9 m/sec, right ventricular hypertrophy by echocardiography, and/or other findings consistent with increased pulmonary hypertension risk: Ensure patient being managed according to NHLBI guidelines83 ; refer to pulmonary hypertension expert for right heart catheterization 
 • TRV of ≥3.0 m/sec: Ensure patient is being managed according to NHLBI guidelines83  and refer to expert in pulmonary hypertension for right heart catheterization 
3. Actions to be taken based on the results of right heart catheterization 
 • mPAP <25 mm Hg: pulmonary hypertension not present: Ensure patient is being managed according to NHLBI guidelines83  and repeat echocardiogram yearly 
 • mPAP ≥25 mm Hg and PCWP ≤15 mm Hg: precapillary pulmonary hypertension 
  – Perform ventilation/perfusion scan of lung and consider long-term anticoagulation if segmental defect found 
  – Refer for overnight polysomnography to evaluate for sleep-disordered breathing including obstructive sleep apnea; provide appropriate intervention if present 
  – Chronic low-flow oxygen by nasal cannula if pulse ox <90% 
  – Refer to expert in pulmonary hypertension for follow-up and consideration whether therapy with endothelin receptor blocker or prostacyclin agent should be attempted* 
  – Consider initiating therapy with hydroxyurea if patient is not receiving this medication or with exchange blood transfusion program if patient does not tolerate or respond to hydroxyurea 
  – Consider allogeneic hematopoietic stem cell transplantation with low-intensity conditioning regimen if patient has HLA-matched sibling. 
 • mPAP ≥25 mm Hg and PCWP >15 mm Hg: postcapillary pulmonary hypertension 
  – Refer to cardiologist to evaluate for left ventricular systolic or diastolic dysfunction; manage according to established guidelines for left ventricular failure74  
  – Consider initiating therapy with hydroxyurea if patient not receiving this medication or with exchange blood transfusion program if patient does not tolerate or respond to hydroxyurea 
  – Consider allogeneic hematopoietic stem cell transplantation with low-intensity conditioning regimen if patient has HLA-matched sibling 
1. Screening for pulmonary hypertension by echocardiography 
 • Perform echocardiography every 1 to 3 y, OR 
 • Perform echocardiography based on one or more findings consistent with increased risk: 
  – Dyspnea on exertion 
  – Limited exercise capability as determined by the 6-minute walk test (<350 m) 
  – History of thromboembolism 
  – Pulse oximetry <96% at rest 
  – Previous echocardiogram with TRV of ≥2.5 m/sec 
  – Physical findings of right-sided heart failure: lower extremity edema, hepatomegaly, or jugular venous distension 
  – Elevated serum N-terminal proBNP concentration 
  – Elevated serum creatinine concentration (>1.0 mg/dL for severe sickling phenotype and >1.4 mg/dL for mild sickling phenotype) 
  – LDH >475 U/L or reticulocyte count >300 000 
  – Serum ferritin >1000 ng/ml 
2. Actions to be taken based on the results of echocardiography 
 • TRV <2.5 m/sec: Ensure that patient is being managed according to NHLBI guidelines83  
 • TRV 2.5-2.9 m/sec, right ventricle normal by echocardiography, no findings suggestive of pulmonary hypertension: Ensure patient being managed according to NHLBI guidelines83  and repeat echocardiogram yearly 
 • TRV 2.5-2.9 m/sec, right ventricular hypertrophy by echocardiography, and/or other findings consistent with increased pulmonary hypertension risk: Ensure patient being managed according to NHLBI guidelines83 ; refer to pulmonary hypertension expert for right heart catheterization 
 • TRV of ≥3.0 m/sec: Ensure patient is being managed according to NHLBI guidelines83  and refer to expert in pulmonary hypertension for right heart catheterization 
3. Actions to be taken based on the results of right heart catheterization 
 • mPAP <25 mm Hg: pulmonary hypertension not present: Ensure patient is being managed according to NHLBI guidelines83  and repeat echocardiogram yearly 
 • mPAP ≥25 mm Hg and PCWP ≤15 mm Hg: precapillary pulmonary hypertension 
  – Perform ventilation/perfusion scan of lung and consider long-term anticoagulation if segmental defect found 
  – Refer for overnight polysomnography to evaluate for sleep-disordered breathing including obstructive sleep apnea; provide appropriate intervention if present 
  – Chronic low-flow oxygen by nasal cannula if pulse ox <90% 
  – Refer to expert in pulmonary hypertension for follow-up and consideration whether therapy with endothelin receptor blocker or prostacyclin agent should be attempted* 
  – Consider initiating therapy with hydroxyurea if patient is not receiving this medication or with exchange blood transfusion program if patient does not tolerate or respond to hydroxyurea 
  – Consider allogeneic hematopoietic stem cell transplantation with low-intensity conditioning regimen if patient has HLA-matched sibling. 
 • mPAP ≥25 mm Hg and PCWP >15 mm Hg: postcapillary pulmonary hypertension 
  – Refer to cardiologist to evaluate for left ventricular systolic or diastolic dysfunction; manage according to established guidelines for left ventricular failure74  
  – Consider initiating therapy with hydroxyurea if patient not receiving this medication or with exchange blood transfusion program if patient does not tolerate or respond to hydroxyurea 
  – Consider allogeneic hematopoietic stem cell transplantation with low-intensity conditioning regimen if patient has HLA-matched sibling 

NHLBI, National Heart, Lung, and Blood Institute.

*

There have been reports that some treatments effective for pulmonary arterial hypertension in patients without SCD also improve SCD-related pulmonary hypertension with hemodynamic parameters consistent with pulmonary arterial hypertension.85-87 

Successful lung transplantation, with intensive pre- and postoperative transfusion support, has been reported in a Hb SS patient with refractory pulmonary hypertension. The patient was maintained with a hemoglobin S percent <10% after transplant through exchange blood transfusion.22 

Close Modal

or Create an Account

Close Modal
Close Modal